<DOC>
	<DOCNO>NCT02794792</DOCNO>
	<brief_summary>The main purpose study evaluate efficacy reduce glycated hemoglobin ipragliflozin combination metformin compare metformin plus placebo subject type 2 diabetes mellitus inadequate glycemic control metformin .</brief_summary>
	<brief_title>A Study Assess Efficacy Safety Ipragliflozin Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control Metformin</brief_title>
	<detailed_description>This phase 3 , double-blind , randomize study ass efficacy safety ipragliflozin combination metformin compare metformin plus placebo subject Russia type 2 diabetes mellitus inadequate glycemic control metformin . Subjects enter 10-day ( ± 3 day ) screen period , follow 2-week single-blind placebo run-in period , follow 24-week randomized double-blind treatment period 4-week follow-up period</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Subject diagnose type 2 diabetes mellitus least 12 week visit 1 . Subject stable dose daily dose regimen metformin ≥ 1500 mg least 12 week prior visit 1 . Subject HbA1c ≥ 7.5 % ≤ 11.0 % visit 1 . Subject stable diet exercise program least 12 week prior visit 1 willing maintain program duration treatment period . Subject body mass index ( BMI ) 20 45 kg/m2 , inclusive , visit 1 . Subjects allow continue take medication concomitant disease ( include overthecounter product ) , provide stable dose minimum 30 day prior visit 1 . Female subject must either : 1 . Be nonchildbearing potential : postmenopausal ( define least 1 year without menses ) prior screen , document surgically sterile 2 . Or , childbearing potential , Agree try become pregnant study 28 day final study drug administration And negative serum pregnancy test visit 1 And , heterosexually active , agree consistently use 2 form highly effective birth control ( least 1 must barrier method ) start screening , throughout study period 28 day final study drug administration . Female subject must agree breastfeed start screening , throughout study period 28 day final study drug administration . Female subject must donate ovum start screening , throughout study period 28 day final study drug administration . Male subject female spouse/partners childbearing potential must use highly effective contraception consist 2 form birth control ( least 1 must barrier method ) start screen continue throughout study period . Male subject must donate sperm start screen throughout study period . Subject type 1 diabetes mellitus . Subject received medication glycemic control , exception metformin , ( e.g. , oral antidiabetic drug , insulin , etc . ) within 12 week prior visit 1 . Subject currently receive exclude medication receive insulin within 12 week prior visit 1 screening period . Subject history stroke , unstable angina , myocardial infarction , vascular intervention heart failure ( New York Heart Association Class IIIIV ; ) within 12 week prior visit 1 . Subject malignancy last 5 year , except adequately treat basal squamous cell carcinoma skin carcinoma situ cervix . Subject history diabetic coma precoma . Subject history ketoacidosis lactic acidosis . History drink 21 unit alcohol per week ( 1 unit = 10 g pure alcohol = 250 mL beer [ 5 % ] 35 mL spirit [ 35 % ] 100 mL wine [ 12 % ] ) ( &gt; 14 unit alcohol female subject ) history drug abuse ( amphetamine , barbiturate , benzodiazepine , cannabinoids , cocaine , opiates ) within 3 month prior visit 1 . Subject know hepatitis carrier hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibody know positive human immunodeficiency virus ( HIV ) 1 and/or HIV2 . Subject severe infection , serious trauma , perioperative subject . Subject symptomatic urinary tract infection genital infection visit 1 and/or prior randomization visit 3 . Subject uncontrolled severe hypertension ( subject whose systolic blood pressure &gt; 180 mmHg diastolic blood pressure &gt; 110 mmHg measure sit position 5 minute rest visit 1 ) . Subject alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) &gt; 2 x upper limit normal ( ULN ) range total bilirubin &gt; 1.5 x ULN visit 1 . Subject urinary microalbumin/creatinine ratio ≥ 300 mg/g visit 1 . Subject estimate glomerular filtration rate ( GFR ) value &lt; 60 mL/min/1.73 m2 visit 1 ( use Modification Diet Renal Disease [ MDRD ] calculation ) . Subject know suspected hypersensitivity ipragliflozin component formulation use history allergy Sodiumglucose cotransporter ( SGLT ) 2 inhibitor . Subject previously receive ipragliflozin SGLT2 inhibitor . Subject concurrently participate another drug study receive investigational drug within 30 day limit set national law , whichever longer , prior visit 1 plan receive another investigational drug study . Female subject currently pregnant lactate Male female subject use appropriate contraception study . The subject unable adhere treatment regimen , protocol procedure study requirement ( include discontinuation criterion runin period ) , investigator 's judgment . Subject unstable medical psychiatric illness .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>ASP1941</keyword>
	<keyword>Ipragliflozin</keyword>
</DOC>